Vermoil

Quick links to important sections

Vermoil

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vermoil

Quick Facts

Property Description
Active ingredient Albendazole (INN)
Form Oral suspension (commonly), Tablets
Pharmacological class Benzimidazole Anthelminthic
Common use Management of Parasitic Worm Infections (Helminthiasis)
Origin Synthetic Compound

The Identity of Vermoil: Defining the Anthelminthic Class

Vermoil is a registered pharmaceutical brand typically prepared as an oral suspension that utilizes the active ingredient Albendazole. It is classified as a synthetic anthelminthic drug, a category specifically designed for the treatment of parasitic worm infestations in humans. Albendazole is chemically a derivative of the Benzimidazole carbamate pharmacological family, a group clinically recognized for its broad-spectrum efficacy against helminths and acknowledged as an essential medicine by the World Health Organization (WHO). This classification confirms the drug's nature as a targeted, chemical compound used to address the condition known as helminthiasis.


Albendazole Composition and Available Pharmaceutical Forms

The core composition of Vermoil is based on a single active ingredient, Albendazole, which acts as the sole therapeutic agent. While Albendazole is commonly available as standard and chewable tablets for oral route administration, Vermoil is often commercially positioned as an oral suspension—a liquid pharmaceutical form where the active substance is uniformly dispersed within a suitable vehicle base. This suspension format is typically favored for use in pediatric patient groups who may experience difficulty swallowing solid medications. The formulation is developed to ensure reliable absorption.


General Therapeutic Purpose and Action Principle

The overarching therapeutic purpose of Vermoil is the systemic clearance and management of parasitic worm infestations by neutralizing the organisms within the host. Albendazole works by selectively disrupting the parasites' cellular functions; for instance, it interferes with the development of essential internal structures, known as microtubules, which are vital for the worm's stability and survival. This targeted action, combined with the inhibition of the parasite's ability to absorb necessary glucose, effectively starves the organism. The consensus among regulatory bodies emphasizes that its mechanism is highly effective for controlling parasitic infections where eradication is the primary goal.

What side effects are possible with Vermoil?

Possible Side Effects and Safety Information

The U.S. Food and Drug Administration (FDA) has issued a Boxed Warning—the agency's strongest warning—concerning the risk of severe and potentially permanent neurologic and psychiatric adverse reactions associated with Vermoil.

Key Warnings and Adverse Reactions

Serious and Clinically Significant Adverse Reactions

  • Neurologic Effects: These may include dizziness, loss of balance (vestibular issues), and ringing in the ears (tinnitus). These symptoms may occur at any time during use, sometimes after only a few doses, and have been documented to persist for months to years after stopping the medication or even become permanent.
  • Psychiatric Effects: These reactions can include anxiety, paranoia, depression, hallucinations, restlessness, confusion, and unusual behavior. Reports of suicidal thoughts and suicidal behavior have also been associated with this medication.

Common Adverse Reactions

The most frequently reported side effects from clinical trials and post-marketing experience generally involve the gastrointestinal and nervous systems. These include nausea, vomiting, diarrhea, abdominal pain, dizziness, difficulty sleeping, and bad dreams.

Safety Considerations and Restrictions

Contraindications

Vermoil is contraindicated for the prevention of malaria in patients with major psychiatric disorders or a history of seizures.

Action for Symptoms

If any signs of neurologic or psychiatric symptoms develop while taking Vermoil for prevention, the drug must be discontinued immediately, and an alternative antimalarial medication should be used.

Overdose and Emergency Response

The official overdose profile for Vermoil (Albendazole) is defined by the risk of severe systemic toxicity and regulator-mandated emergency actions.

Category Documented Manifestations & Actions
Documented Manifestations Clinical presentations documented in regulatory sources may include headache, dizziness, nausea, vomiting, or fever. Of critical concern are severe outcomes such as Acute Liver Failure or fatalities linked to Bone Marrow Suppression (e.g., pancytopenia, agranulocytosis).
Urgent Medical Action Immediate medical help must be sought if an overdose is suspected. The official labeling specifies calling emergency services if the individual has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened. Contacting a Poison Control center is also mandated.
Overdose Management Profile Regulatory Constraints
Supportive Care Management is defined as symptomatic and supportive treatment. No specific antidote is known. Procedures include discontinuation of therapy if clinically significant drops in blood counts or enzyme elevations occur.
Monitoring & Risk The official documentation requires close monitoring of blood counts and liver enzymes. Patients with pre-existing liver disease are documented to be at increased risk for severe bone marrow suppression (e.g., aplastic anemia) following excessive exposure.

Therapeutic Uses of Vermoil

What Vermoil Treats: Main Uses and Benefits

Vermoil is generally applied as supportive care to assist with temporary, disruptive symptoms across several clinical domains, primarily used for temporary symptomatic support. This type of non-prescription management is commonly indicated for the temporary easing of a variety of acute and episodic symptoms.


Easing Sudden and Intensified Symptom Clusters

This medication helps address symptom clusters that may appear suddenly or intensify over time, creating noticeable interference with daily stability. The support provided may assist with easing the overall symptom load and help patients cope during episodes of temporary discomfort. It is considered relevant for use in conditions characterized by periods of heightened symptoms or **fluctuating manifestations.


Supportive Care for Episodic Discomfort

Vermoil is commonly used across conditions presenting with acute episodes and is applied in contexts where additional symptomatic support is needed. It may assist with improving comfort during periods of heightened symptoms and supports general well-being when symptoms are more noticeable. Generally, it is applied in addressing symptoms related to physical discomfort or systemic imbalance.


Quick Fact: Support for Temporary Discomfort Vermoil may assist with easing the symptom load during phases of increased distress or discomfort.

Regulatory References

  1. Health Canada Guidance Document: Non-prescription Oral Adult Cough, Cold and Flu Labelling Standard

Eligibility and Restrictions for Use

Population Eligibility and Contraindications

Vermoil (Albendazole) eligibility is strictly defined by regulatory authorities based on age, reproductive status, and pre-existing conditions.


Non-Eligibility Status

Use is prohibited for patients with a known hypersensitivity to albendazole or any compound in the benzimidazole class. The medicine is formally contraindicated in pregnant women due to the potential for fetal harm. Female patients of reproductive potential must obtain a negative pregnancy test prior to initiation and must use an effective method of contraception during and for a specified period following treatment. Use is also not recommended for children under 2 years of age due to limited clinical experience.


Conditional Use and Monitoring

Special caution is required for patients with pre-existing or active Liver Disease (Hepatic Impairment), necessitating close monitoring of liver enzymes; treatment may be discontinued if elevations are significant. Caution is also advised for patients with compromised Renal Impairment and those with a predisposition for Bone Marrow Suppression. Furthermore, patients with known Ocular Cysticercosis must undergo a pre-treatment retinal examination to assess risks.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Vermoil (Albendazole) is primarily defined by the way other substances officially alter the plasma concentration of its active metabolite, Albendazole sulfoxide. Regulatory documents describe several clinically significant pharmacokinetic interactions.

Drug–Drug Interactions and Exposure Modification

Classification Interacting Agents Official Outcome
Increased Exposure Dexamethasone, Praziquantel, Cimetidine Dexamethasone increases steady-state concentrations by approximately 56%; Praziquantel increases AUC/Cmax by about 50%; Cimetidine increases concentrations in bile and cystic fluid by two-fold.
Decreased Exposure Phenytoin, Rifampin, Ritonavir, Carbamazepine Strong enzyme inducers decrease active metabolite plasma levels, risking reduced therapeutic efficacy.
Additive Toxicity Myelosuppressive agents (e.g., Ropeginterferon alfa 2b) Official risk of additive effects leading to bone marrow suppression.

Food and Substance Interactions

Co-administration with fat-containing meals is required as it significantly enhances the absorption and systemic availability of the active metabolite. In contrast, Grapefruit Juice is documented to increase the plasma levels of Albendazole sulfoxide by interfering with specific metabolic enzymes.

Population-Specific Notes

Regulatory information notes that patients with liver disease and hepatic echinococcosis face an increased risk of bone marrow suppression when receiving this medication, necessitating caution.

Mechanism of Action

How Vermoil Works


Inhibiting Cellular Structure and Function

Vermoil’s mechanism begins at the molecular level by functioning as a high-affinity inhibitor of the target organism’s beta-tubulin subunits. This binding prevents the polymerization of alpha and beta tubulin, which disrupts the assembly of microtubules—essential components of the cytoskeleton. This action compromises the structural integrity and intracellular transport functions of the organism's cells, initiating the disruption of fundamental cellular processes.


Blocking Nutrient Uptake and Energy Pathways

The structural damage cascade extends into the organism's digestive function. Vermoil interferes with microtubule-dependent glucose transport and uptake, directly blocking the absorption of necessary energy substrates. This interference results in the cessation of energy substrate availability, affecting key metabolic processes and forcing the organism to deplete its endogenous energy reserves (glycogen).


Physiological Collapse and Immobilization

The convergence of structural compromise and total energy deprivation dictates the organism's functional status. The combined effect of cytoskeletal failure and metabolic collapse causes the organism to lose motility, leading to the physiological collapse and cessation of function.

Dosage and Administration Information

How to Use Vermoil

Vermoil (Albendazole) administration is defined by specific protocols to ensure appropriate absorption and systemic exposure. The medicine is administered exclusively by the oral route and is available as tablets (commonly 200 mg or 400 mg strengths) and an oral suspension.

Administration and Timing

For treatments targeting systemic or tissue infections, the dose must be taken with food, as consuming the medicine with a meal significantly enhances its absorption for maximum effect. The specific dosing regimen varies based on the type of infection being managed, ranging from a single 400 mg dose for certain common infections to 400 mg taken twice daily (BID) for systemic conditions.

Treatment Structure and Duration

Treatment courses are highly structured. For some infections, the regimen may involve a short course of only 1 to 3 days, or a single dose that may be repeated after two weeks. For complex, long-term conditions like Hydatid Disease, the drug is administered in defined 28-day cycles, followed by a 14-day drug-free interval, which is then repeated for a prescribed total number of cycles.

Population-Specific Use

Dosage for pediatric patients is often calculated using a weight-based formula of 15 mg/kg/day divided into two daily doses. General clinical parameters indicate that dose adjustment is generally not necessary for patients with renal impairment, as the drug is minimally excreted by the kidneys. To facilitate proper intake, tablets are designed to be crushed or chewed and swallowed with water if a patient has difficulty swallowing the whole tablet.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Vermoil

The active ingredient in Vermoil, Albendazole, was studied in various trial designs, including randomized controlled trials (RCTs) and systematic reviews. These studies were designed to explore outcomes related to the presence of parasites and related clinical measures. Findings describe group patterns, not personal outcomes, and research provides context but not individual predictions.


Evidence for Use in Soil-Transmitted Helminthiasis (STH) Studies

Research has primarily relied on RCTs, examining outcomes related to microbiological measures, specifically tracking the conversion of infected individuals to egg-negative status (Cure Rate) and the overall reduction of parasite egg counts (Egg Reduction Rate) in populations, often school-aged children and adults.

For roundworm (Ascaris lumbricoides), studies tracked measurements of microbiological count across various regimens. For hookworm, the outcomes were more variable. Single-dose regimens reported outcomes related to parasite count, while multi-dose regimens were observed with different measurements in some studies. Against whipworm (Trichuris trichiura), the outcomes related to parasite count reported in trials are generally lower, and the evidence is limited compared to the other two species.


Evidence for Use in Neurocysticercosis and Hydatid Disease

For systemic infections that form cysts in organs, researchers monitored outcomes using specialized radiological endpoints, such as CT or MRI scans, to measure the change in the number, size, or appearance of the active cysts. Studies on Neurocysticercosis also examined outcomes related to patient seizure frequency.

In studies of Neurocysticercosis, findings described patterns of measurements of cyst size and appearance on imaging scans following treatment. However, reports on the long-term effects on seizure frequency and recurrence are not fully established and findings were mixed across different trials. Data for specific patient groups, such as pregnant individuals or those with severe underlying conditions, remain insufficient or are limited to highly specialized clinical reports. The results apply only to the populations studied in the original trials.

Frequently Asked Questions (FAQ)

Common questions about Vermoil (FAQ)

Q: Is Vermoil the same type of medication as [Similar Drug Name]?

A: Vermoil's active ingredient, Albendazole, is chemically classified as a benzimidazole anthelminthic. This is a specific category of medicine used to treat parasitic worm infections. Other medications, like mebendazole or thiabendazole, belong to the same pharmacological class, however, their specific indications or pharmacokinetic profiles may differ, according to regulatory documents.

Q: Is it normal to feel tired when first starting Vermoil?

A: Official regulatory information notes that both fatigue (feeling tired) and weakness are symptoms that have been reported with the use of this medicine. It is important to know that these symptoms can sometimes be associated with more serious issues, such as low blood cell counts. Official patient information indicates these symptoms should be discussed with a healthcare professional.

Q: Why do some people say Vermoil didn't work for them?

A: Studies and official information indicate that the success rate of treatment can vary depending on several factors. This includes the specific type of parasitic infection being managed and the prescribed duration of the treatment course. Regulatory summaries focus on group patterns observed in clinical trials, which do not guarantee any single patient's specific outcome.

Q: Can taking Vermoil make me dizzy or affect my driving?

A: Official drug labeling lists dizziness as a commonly reported side effect, and it is also included in the warnings for serious reactions. Due to the potential for dizziness, official warnings advise that caution should be used before engaging in activities requiring full mental alertness.

Q: Is Vermoil used for other conditions besides what it's mainly approved for?

A: The U.S. FDA has granted official approval for Vermoil to be used in the management of neurocysticercosis and hydatid disease. The active ingredient is a broad-spectrum anthelminthic, and regulatory documents indicate that the active ingredient may also be employed in treating several other parasitic infections, such as roundworm and hookworm, when medically determined.

Q: Can Vermoil be crushed or mixed with food if swallowing is difficult?

A: According to official product information, if a patient has difficulty swallowing the tablet form of Vermoil, the tablets are approved to be crushed or chewed. The product information states that the crushed or chewed tablet should be swallowed with water. This instruction is provided to help facilitate the administration of the medicine.

Q: Is the ingredient list for Vermoil publicly available?

A: Yes, regulatory standards require the disclosure of key information about the medicine's composition. Official documentation, such as the FDA labeling and Safety Data Sheets, confirms that the active ingredient is Albendazole. This documentation generally also discloses the inactive ingredients necessary for the product's formulation.

Q: Has Vermoil been recalled or flagged for safety issues recently?

A: The most significant safety measure associated with this product is the official Boxed Warning issued by the FDA. This Boxed Warning represents the strongest regulatory safety warning available for a medication, highlighting the potential risk of severe and potentially permanent neurologic and psychiatric adverse reactions.

Q: What is the typical timeframe before knowing if Vermoil is effective?

A: The timeframe for determining effectiveness is dependent on the infection being treated, as treatment duration varies widely. Courses can range from a single dose to structured, repeated cycles lasting up to several months for complex conditions. Efficacy is not based on immediate patient perception but is determined by a healthcare professional through medical monitoring throughout the prescribed treatment course.

Q: Why is Vermoil restricted to prescription only?

A: Prescription status is required for Vermoil because of the potential for serious adverse reactions, including bone marrow suppression and neurological issues, that have been noted in regulatory warnings. The drug’s safety profile indicates a need for medical supervision, which typically involves routine laboratory testing.

Q: Is it true that Vermoil requires kidney function monitoring?

A: Regulatory information advises that special caution is required for patients with pre-existing renal impairment (kidney disease). While dose adjustments are typically not necessary because the drug is minimally excreted by the kidneys, regulatory guidance indicates that monitoring is still required for patients with compromised kidney function during treatment.

Q: What should I do if I forget to take my Vermoil dose?

A: Official guidance states that if a dose is missed, the medicine should be taken as soon as it is remembered. However, if it is almost time for your next scheduled dose, the instruction is to skip the missed dose and resume the normal routine. It is explicitly stated that you should not take double or extra doses to compensate for a missed one.

Q: Are there any common over-the-counter pain relievers that interact with Vermoil?

A: Official drug interaction lists do not typically categorize common over-the-counter pain relievers as having major or moderate interactions that alter how Vermoil works. However, due to the potential for liver risk, official warnings note the need for caution when co-administering any other substance that may affect the liver.

Q: Can older adults take Vermoil safely?

A: Official guidance states that generally no specific dose adjustment is required for elderly patients. However, official guidance indicates that healthcare professionals typically monitor older adults for general adverse reactions during treatment.

Q: Does Vermoil stay in your system for a long time?

A: The speed at which a drug leaves the body is described by its elimination half-life. The active substance derived from Vermoil, Albendazole sulfoxide, has a half-life measured in studies to be approximately 8.5 hours in most people. This means that the concentration of the active medicine in the body declines measurably over several hours.

Q: Can I take Vermoil with vitamins or herbal supplements?

A: Official patient guidance emphasizes the need to fully disclose all medications, including vitamins and herbal products, to the prescribing doctor. This is to ensure the healthcare professional can screen for potential risks or interactions.

Q: Is Vermoil known to interact with alcohol?

A: Regulatory guidance indicates that alcohol consumption is generally discouraged while taking the medication. The concern is related to the increased risk of liver damage, or hepatotoxicity, because both alcohol and the drug's active ingredient are processed by the liver.

Q: If I miss a dose of Vermoil, should I take two doses next time?

A: The instruction for missed doses is clear: you should not take double or extra doses to attempt to make up for a dose you have forgotten. This direction is provided in official patient information to avoid a potential overdose.

Q: Why is Vermoil sometimes prescribed with another medicine?

A: In some complex treatment regimens, Vermoil is prescribed alongside other medicines. This is done to help manage symptoms related to the condition, or to facilitate the overall treatment process. For instance, in treating neurocysticercosis, the drug may be part of a broader therapeutic plan.

Q: Is there a patient information leaflet that comes with Vermoil?

A: Yes, official regulations require that all prescription medications, including Vermoil, be supplied with a Patient Information sheet or leaflet. This document contains vital safety warnings, proper administration instructions, and other information that the patient should review.

Q: Does the time of day matter when taking Vermoil?

A: Regulatory guidance states that the medicine should be taken at around the same times every day throughout the treatment course. This practice is important for maintaining consistent drug levels in the bloodstream, which is essential for proper treatment efficacy.

Q: What are the guidelines for discontinuing Vermoil after treatment is finished?

A: Official patient guidelines advise that the medicine should be taken for the full prescribed length of time as directed by the doctor. It is important to complete the entire course of treatment, even if a person begins to feel better, to ensure the condition is fully managed.

Q: Can Vermoil affect the results of certain medical tests?

A: While the drug is not generally reported to interfere with laboratory tests, the treatment itself requires regular lab work and examinations. These tests are part of the required protocol to monitor the patient for any adverse reactions or changes during the course of treatment.

Q: What happens if a child accidentally swallows Vermoil?

A: In the event of a suspected overdose or accidental ingestion by a child, official guidance emphasizes immediately calling emergency services if the person has collapsed, is having a seizure, has difficulty breathing, or cannot be awakened.

How should Vermoil be stored and disposed of?

How to Store and Dispose of Vermoil

The storage and disposal of Vermoil must strictly adhere to the conditions mandated in official regulatory labeling to ensure product stability and safety.

Official Storage Requirements

Condition Requirement (from Regulatory Labeling)
Temperature Store at a Controlled Room Temperature, typically 25 C (77 F), with excursions allowed up to 30 C (86 F).
Container Keep in the original container and maintain the container tightly closed and protected from light and moisture.
Prohibition Do not freeze the medication.
Safety Store this medicine out of the sight and reach of children.

Disposal Instructions

Unused or expired Vermoil must be disposed of in accordance with local requirements for pharmaceutical waste. Do not dispose of the medication via wastewater or household trash, as this is prohibited by official guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vermoil found in:

A-Z Index: